326 related articles for article (PubMed ID: 29210655)
1. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
Athyros VG; Katsiki N; Doumas M
Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
[No Abstract] [Full Text] [Related]
2. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
3. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
4. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
5. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Muzurović E; Smolović B; Vujošević S; Petakov M
Curr Vasc Pharmacol; 2021; 19(5):582-584. PubMed ID: 33032512
[No Abstract] [Full Text] [Related]
6. Nonalcoholic fatty liver disease and statins.
Tziomalos K; Athyros VG; Paschos P; Karagiannis A
Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
[TBL] [Abstract][Full Text] [Related]
7. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
Athyros VG; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814
[No Abstract] [Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
11. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
[TBL] [Abstract][Full Text] [Related]
12. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
14. Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments.
Athyros VG; Koumaras C; Sfikas G
Curr Vasc Pharmacol; 2021; 19(6):673-674. PubMed ID: 33327917
[No Abstract] [Full Text] [Related]
15. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease: Current Concepts.
Tziomalos K
Curr Pharm Des; 2018; 24(38):4564-4565. PubMed ID: 30885115
[No Abstract] [Full Text] [Related]
17. Modern approach to the clinical management of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
[TBL] [Abstract][Full Text] [Related]
18. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
19. Statins in liver disease: not only prevention of cardiovascular events.
Magan-Fernandez A; Rizzo M; Montalto G; Marchesini G
Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):743-744. PubMed ID: 29768950
[No Abstract] [Full Text] [Related]
20. [Non-alcoholic liver disease - diagnosis and treatment].
Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
